From Medscape Dermatology

Coverage from the

American Academy of Dermatology (AAD) 2023 Annual Meeting

March 17 - 21, 2023; New Orleans, Louisiana

March 17 - 21, 2023 New Orleans, Louisiana

AAD 2023 New Data Forecast More Oral PDE4 Inhibitors for Psoriasis A new oral phosphodiesterase-4 (PDE4) inhibitor achieved impressive rates of complete or near-complete skin clearance in a phase 2 study that also found the drug was well tolerated.
Medscape Medical News, March 24, 2023
AAD 2023 New JAK Inhibitor Study Data Confirm Benefit in Alopecia Areata The investigational drug deuruxolitinib is effective for hair regrowth in patients with alopecia areata, putting it in line to become second approved JAK inhibitor.
Medscape Medical News, March 23, 2023
AAD 2023 Dermatomyositis: Data Support IFN-Beta as Therapeutic Target Response rates in a phase 2 trial of a novel therapy for skin-predominant dermatomyositis were favorable in patients failed by at least one prior standard therapy, prompting plans for a phase 3 trial.
Medscape Medical News, March 20, 2023

Disclaimer: This coverage is not sanctioned by, nor a part of, the American Academy of Dermatology.

Conference News

AAD 2023 Starting Baricitinib Early for Severe Alopecia Areata Beneficial
Medscape Medical News, April 11, 2023
AAD 2023 Clinical Implications of Recent Skin Dysbiosis Discoveries
MDedge News, April 6, 2023
AAD 2023 Practicing Ethical Medicine 'A Requirement,' Not a Luxury
MDedge News, April 6, 2023
AAD 2023 Demand for Experienced Skin Care of Asian Americans to Increase
MDedge News, March 31, 2023
AAD 2023 Limited Treatment Options Exist for Brittle Nail Syndrome
MDedge News, March 29, 2023
AAD 2023 Another JAK Inhibitor Shows Efficacy for Atopic Dermatitis
Medscape Medical News, March 28, 2023
AAD 2023 Topical Delgocitinib Effective for Hand Eczema in Phase 3 Trial
MDedge News, March 27, 2023
AAD 2023 New Data Forecast More Oral PDE4 Inhibitors for Psoriasis
Medscape Medical News, March 24, 2023
AAD 2023 New JAK Inhibitor Study Data Confirm Benefit in Alopecia Areata
Medscape Medical News, March 23, 2023

AAD 2023 Expert Shares Her Tips for Diagnosing, Treating Onychomycosis
MDedge News, March 23, 2023
AAD 2023 Phase 3 Prurigo Nodularis Trial Shows Benefit With Nemolizumab
MDedge News, March 22, 2023
AAD 2023 Dermatomyositis: Data Support IFN-Beta as Therapeutic Target
Medscape Medical News, March 20, 2023
AAD 2023 Studies Validate IL-17 as Hidradenitis Suppurativa Drug Target
Medscape Medical News, March 20, 2023
AAD 2023 Novel Single-Use Patch Shows Promise for Axillary Hyperhidrosis
MDedge News, March 19, 2023
AAD 2023 Biomarkers for Treatment Response Evaluated in Children With CSU
MDedge News, March 19, 2023
AAD 2023 Dermatology Risks Are Likely Different for JAK Inhibitors
Medscape Medical News, March 18, 2023
AAD 2023 YouTube Content on Topical Steroid Withdrawal Subpar Study Finds
MDedge News, March 17, 2023

Medscape Dermatology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Popular News from AAD 2022

New Trial Data Show Hair Growth in More Alopecia Areata Patients At 52 weeks, nearly 40% of people taking the higher dose of baricitinib had scalp hair coverage of 80% or more, according to updated clinical trial data.
Medscape Medical News, Mar 26, 2022
Study Links COVID-19 to Autoimmune and Vascular Diseases Information regarding development of autoimmune disease following SARS-CoV-2 infection has been limited, according to one of the investigators.
Medscape Medical News, Mar 26, 2022
Clinical Clarity Grows About Toenail Disorder, Experts Report The hallmark of retronychia, a disorder of the toes, is layering of new nail growth under prior nail growth. The etiologies vary, affecting treatment choice and likelihood of long-term response.
Medscape Medical News, Mar 27, 2022

Previous Coverage

Related Resources